Skip to main content
This site is intended for US healthcare professionals only.

MIM Software Setup Instructions

Follow these step-by-step instructions to set up MIM software on your computer, or download the MIM Setup Guide.

Note: Due to rapid advances in and frequent updates to software, your version of MIM may look different. However, the tools and steps remain the same.

  1. Please click on a link below to download the appropriate installer for the MIM Referring software.

    For PC/Windows users: https://downloads.mimsoftware.com/MIM7.0.6_buildKB13-05.exe
    For Mac users: https://downloads.mimsoftware.com/MIM7.0.6_buildKB13-05.dmg

    For PC/Windows users:
    For Mac users:

  2. Install the application.

    • For PC/Windows users: click Run as Administrator to begin the download and follow the installation instructions; see screenshot below.

      For PC/Windows users: click Run as Administrator to begin the download and follow the installation instructions; see screenshot below.

    • For Mac users: click on the downloaded .dmg file and then click on the PKG file to begin the installation.

      For Mac users: click on the downloaded .dmg file and then click on the PKG file to begin the installation.

  3. Enter the password korey (all lowercase) when prompted; see screenshot below.

    Enter the password korey (all lowercase) when prompted; see screenshot below.

  4. Once the installation completes, you will need to accept the end user license agreement and click Next; see screenshot below.

    Once the installation completes, you will need to accept the end user license agreement and click Next; see screenshot below.

  5. To configure the install, you can accept the file install location default choice or change it if desired; then click Next.

    To configure the install, you can accept the file install location default choice or change it if desired; then click Next.

  6. The next step asks if you’d like to create a shortcut; leave the selection at “All Users” and click Install; see screenshot below.

    The next step asks if you’d like to create a shortcut; leave the selection at “All Users” and click Install; see screenshot below.

  7. MIM will install.

    MIM will install.

  8. Once finished installing, MIM will load after you click “Start MIM.”

    Once finished installing, MIM will load after you click “Start MIM.”

  9. For the licensing option, select the top drop-down menu and switch from “Fixed” to “MIMCloud License” and enter the log-in credentials provided below.

    • Username: TAUVID@TAUVIDReaderTraining.com
    • Password: Tauvid2021

    For the licensing option, select the top drop-down menu and switch from “Fixed” to “MIMCloud License” and enter the log-in credentials provided below.

  10. After entering the username and password listed in Step 9, select “MIM Referring” as your License Selection; then click OK to continue

    For the licensing option, select the top drop-down menu and switch from “Fixed” to “MIMCloud License” and enter the log-in credentials provided below.

Indication

TAUVID is indicated for use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD).


Limitations of Use
TAUVID is not indicated for use in the evaluation of patients for chronic traumatic encephalopathy (CTE).

  • TAUVID for intravenous use is supplied in multidose vials containing 300 MBq/mL to 3700 MBq/mL flortaucipir F 18.

Indication

TAUVID is indicated for use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD).


Limitations of Use
TAUVID is not indicated for use in the evaluation of patients for chronic traumatic encephalopathy (CTE).

  • TAUVID for intravenous use is supplied in multidose vials containing 300 MBq/mL to 3700 MBq/mL flortaucipir F 18.
Important Safety Information

Risk of Misdiagnosis in Patients Evaluated for Alzheimer's disease (AD)
 TAUVID does not target β-amyloid, one of two required components of the neuropathological diagnosis of AD. TAUVID performance for detecting tau pathology was assessed in terminally ill patients, the majority of whom had AD dementia with B3 level neurofibrillary tangle (NFT) pathology. TAUVID performance for detecting tau pathology may be lower in patients in earlier stages of the pathological spectrum.

Negative TAUVID Scan
NFTs may be present at levels that qualify for the neuropathological diagnosis of AD (B2 tau pathology in the presence of at least moderate levels of cortical amyloid pathology) in patients with a negative TAUVID scan. Consider additional evaluation to confirm the absence of AD pathology in patients with a negative TAUVID scan.

False Positive TAUVID Scan
Small foci of noncontiguous tracer uptake may lead to a false positive TAUVID scan. Only uptake of tracer in the neocortex should contribute to the interpretation of a positive TAUVID scan.

Risk of Chronic Traumatic Encephalopathy Misdiagnosis
 The safety and effectiveness of TAUVID have not been established for patients being evaluated for CTE. Preliminary non-clinical and clinical investigations suggest differences in tau conformation and distribution may limit flortaucipir F 18 binding. Therefore, TAUVID is not indicated for detection of CTE.

Radiation Risk
Diagnostic radiopharmaceuticals, including TAUVID, expose patients to radiation. Radiation exposure is associated with a dose-dependent increased risk of cancer. Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure.

ADVERSE REACTIONS
 The most common adverse reactions reported in clinical trials were headache (1.4%), injection site pain (1.2%), and increased blood pressure (0.8%).

USE IN SPECIFIC POPULATIONSPregnancyAll radiopharmaceuticals, including TAUVID, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude radiation dose. Advise a pregnant woman of the potential risks of fetal exposure to radiation doses with administration of TAUVID.

LactationAdvise a lactating woman to avoid breastfeeding for 4 hours after TAUVID administration in order to minimize radiation exposure to a breastfed infant.

Please see Full Prescribing Information for TAUVID.

FT HCP ISI 14SEP2022

Indication

TAUVID is indicated for use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD).

Limitations of Use
TAUVID is not indicated for use in the evaluation of patients for chronic traumatic encephalopathy (CTE).

  • TAUVID for intravenous use is supplied in multidose vials containing 300-3700 Mbq/mL flortaucipir F 18.
Important Safety Information

Risk of Misdiagnosis in Patients Evaluated for Alzheimer's disease (AD)
 TAUVID does not target β-amyloid, one of two required components of the neuropathological diagnosis of AD. TAUVID performance for detecting tau pathology was assessed in terminally ill patients, the majority of whom had AD dementia with B3 level neurofibrillary tangle (NFT) pathology. TAUVID performance for detecting tau pathology may be lower in patients in earlier stages of the pathological spectrum.

Negative TAUVID Scan
NFTs may be present at levels that qualify for the neuropathological diagnosis of AD (B2 tau pathology in the presence of at least moderate levels of cortical amyloid pathology) in patients with a negative TAUVID scan. Consider additional evaluation to confirm the absence of AD pathology in patients with a negative TAUVID scan.

False Positive TAUVID Scan
Small foci of noncontiguous tracer uptake may lead to a false positive TAUVID scan. Only uptake of tracer in the neocortex should contribute to the interpretation of a positive TAUVID scan.

Risk of Chronic Traumatic Encephalopathy Misdiagnosis
 The safety and effectiveness of TAUVID have not been established for patients being evaluated for CTE. Preliminary non-clinical and clinical investigations suggest differences in tau conformation and distribution may limit flortaucipir F 18 binding. Therefore, TAUVID is not indicated for detection of CTE.

Radiation Risk
Diagnostic radiopharmaceuticals, including TAUVID, expose patients to radiation. Radiation exposure is associated with a dose-dependent increased risk of cancer. Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure.

ADVERSE REACTIONS
 The most common adverse reactions reported in clinical trials were headache (1.4%), injection site pain (1.2%), and increased blood pressure (0.8%).

USE IN SPECIFIC POPULATIONSPregnancyAll radiopharmaceuticals, including TAUVID, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude radiation dose. Advise a pregnant woman of the potential risks of fetal exposure to radiation doses with administration of TAUVID.

LactationAdvise a lactating woman to avoid breastfeeding for 4 hours after TAUVID administration in order to minimize radiation exposure to a breastfed infant.

Please see Full Prescribing Information for TAUVID.

FT HCP ISI 14SEP2022

Indication

TAUVID is indicated for use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD).

Limitations of Use
TAUVID is not indicated for use in the evaluation of patients for chronic traumatic encephalopathy (CTE).

  • TAUVID for intravenous use is supplied in multidose vials containing 300-3700 Mbq/mL flortaucipir F 18.